FDA’s Rx Administrative Detention Reg Coming, But Not For A Little While
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency asks for stakeholder comments in advance of issuing a proposed rule on its new authority to detain potentially misbranded or adulterated drugs found during inspections, which was among FDASIA-mandated supply chain security improvements.